Final Settlement Approved in Plasma-Derivative Protein Therapies Antitrust Case

Posted: 04/21/2014 | Share This Post

On Thursday, April, 17, 2014, United States District Court Judge Joan B. Gottschall granted final approval of the settlement between Plaintiffs and the only remaining Defendants, Baxter International, Inc., and Baxter Healthcare Corporation, in the In Re Plasma-Derivative Protein Therapies Antitrust Litigation, pending in the Northern District of Illinois.   This settlement with Baxter for $64 million brings the total amount recovered by Plaintiffs, represented by Charles Tompkins of Williams, Montgomery and John Ltd. and Richard Koffman of Cohen, Milstein, Sellers and Toll, PLLC, to $128 million. Earlier this year, the Court approved a settlement between Plaintiffs and defendants CSL Limited, CSL Behring LLC, CSL Plasma Inc., and the Plasma Protein Therapeutics Association in the identical amount of $64 million.  Charles Tompkins said of the settlements, "the result obtained on behalf of the corporate clients we represent here is one that fairly compensates them for the losses they suffered without the need for further protracted litigation."  Mr. Koffman commented that the resolution of this litigation is "an outstanding result that achieves justice for more than 2,000 class members.  The settlements have been very well received by the many class members to whom I have spoken, which I find deeply gratifying."